ASAlexander Sturm

Alexander Sturm

*This is an algorithmically generated author record based on publicly available information.

Alexander Sturm has a total of 133 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rapid delineation of Acinetobacter baumannii dose responses to zosurabalpin based on machine learning-assisted interpretation of bacterial nanomotions

    by Marta Pla Verge, Jan Winnicki, Amanda Luraschi-Eggemann, Grzegorz Jozwiak, Katja Fromm, Laura Munch, Gino Cathomen, Caspar Vogel, Florian Schwanke, Danuta Cichocka, et al.

    Carbapenem-resistant Acinetobacter baumannii (CRAB) represents a major clinical threat, underscoring the urgent need for both new antibiotics and rapid antimicrobial susceptibility testing (AST) methods that can inform treatment. Here, we describe a susceptibility assessment that combines nanomotion technology with machine learning (ML) to rapidly classify responses to zosurabalpin (ZAB), the first-in-class antibiotic targeting the LptB₂FGC complex of the lipopolysaccharide transport pathway in A. baumannii . Nanomotion recordings from five A. baumannii strains spanning a wide range of minimum inhibitory concentrations (MICs) were measured at multiple ZAB concentrations. A logistic regression ML model was trained using a labeling strategy that categorized recordings as susceptible or non-susceptible based on strain MICs obtained by reference methods and antibiotic concentrations measured. This model, built on four quantile features, achieved >90% accuracy compared with susceptibility responses. These results highlight four key advances: (i) nanomotion-based AST can deliver reliable phenotypic classification for new antibiotics before clinical breakpoints are available, (ii) accurate results can be obtained within only 2 h, (iii) the method extends nanomotion’s applicability to high-priority pathogens, such as CRAB, and (iv) the nanomotion response can reflect early cellular changes that precede a measurable decline in viability, suggesting that susceptibility may be detected before killing becomes apparent by conventional methods. Together, this work establishes nanomotion-ML AST as a promising diagnostic platform to support the evaluation and future integration of novel drugs into clinical practice, advancing next-generation rapid AST workflows against critical multidrug-resistant pathogens. IMPORTANCE: This study demonstrates a rapid, nanomotion-based approach with potential to inform antibiotic susceptibility assessment for Acinetobacter baumannii infections. By combining nanomotion technology with quantitative machine-learning-assisted signal analysis, susceptibility to the novel antibiotic zosurabalpin, which is currently in clinical development, could be determined within 2 h. The assay reliably distinguished susceptible from non-susceptible phenotypes across strains with different MICs and in both standard and horse serum-supplemented media. Notably, the nanomotion signature reflected early cellular responses that preceded a measurable decline in viability by conventional methods. Together, these features provide rapid phenotypic insights that may support future development of timely, targeted therapy decisions. The findings highlight nanomotion-based antimicrobial susceptibility testing as a promising tool to accelerate diagnostic readiness for new antibiotics and improve treatment management in infections caused by multidrug-resistant A. baumannii .

  • Open Access

    Nanomotion-enabled ultra-rapid antibiotic susceptibility testing with magnetic bead-based pathogen enrichment for accelerated sepsis diagnostics

    by Grzegorz Jóźwiak, Marta Pla Verge, Amanda Luraschi-Eggemann, Cyrine Mestiri, Elinor McSorley, Daisy Wilson-Owen, Sonia La Fauci, María García-Castillo, Eric Delarze, Katja Fromm, et al.

    Rapid and accurate antimicrobial susceptibility testing (AST) is critical for guiding therapy in life-threatening infections such as sepsis, but current diagnostics rely on blood culture, delaying results by 48–72 h. This time lag forces empirical use of broad-spectrum antibiotics, increasing risks of treatment failure and antimicrobial resistance. We developed an approach combining bacterial growth-independent nanomotion detection with magnetic bead–based enrichment directly from blood. Using machine-learning classifiers trained on nanomotion spectra, we established ten antibiotic-specific models across 1,337 blood culture samples containing 390 clinical isolates of Enterobacterales (e.g., Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae) and Pseudomonas aeruginosa. These models achieved 94–98% sensitivity and specificity with fixed 2-h readouts. In parallel, SepsiSTAT enrichment enabled rapid recovery of viable bacteria and yeast at clinically relevant concentrations from 10 mL blood, with time-to-positivity averaging 5.5 h, i.e., over 7 h faster and more predictable than conventional blood culturing. The workflow was afterwards adapted to 1 mL input volumes, compatible with blood volume sampling constraints in fragile patient groups such as geriatric or neonatal patients. In spiked E. coli blood samples, ceftriaxone susceptibility was determined within 9–11 h of collection, nearly two days earlier than current standards. By integrating enrichment with nanomotion AST, we introduce a low-volume, label-free, phenotypic diagnostic platform capable of delivering actionable results within clinically meaningful timeframes. This approach holds potential to improve antibiotic stewardship, enable earlier transition from empiric to targeted therapy, and expand diagnostic access for vulnerable populations such as neonates.


  • Open Access

    Nanomotion-Based Drug Sensitivity Prediction in Ovarian and Colon Cancer Cell Lines Using Machine Learning

    by Katja Fromm, Jan Winnicki, Grzegorz Jóźwiak, Gino Cathomen, Christine Wagner, Marta Pla Verge, Eric Delarze, Michał Świątkowski, Grzegorz Wielgoszewski, Maria Ines Villalba, et al.

    Cancer drug resistance remains a critical challenge in oncology, demanding rapid and reliable diagnostic tools to assess tumor cell susceptibility to treatment. This study presents a nanomotion-based drug susceptibility testing (DST) approach, integrating nanoscale movement analysis with supervised machine learning to classify drug-sensitive and drug-resistant cancer cells. Using label-free, real-time nanomotion technology, we measured the dynamic responses of colon cancer (SW480) and ovarian cancer (A2780, A2780ADR) cells to doxorubicin under physiological conditions. Features extracted from nanomotion signals were used to train machine learning models, achieving 90.9% accuracy in distinguishing between doxorubicin-treated and untreated SW480 cells and 84.6% accuracy in classifying doxorubicin-sensitive and -resistant ovarian cancer cells. The model achieved perfect classification of resistant A2780ADR cells in an independent test set after only 4 h and 15 min of exposure to the drug. Unlike genetic tests that infer drug resistance from molecular markers or metabolic assays requiring extended incubation times, nanomotion-based DST provides a direct phenotypic readout, offering a faster, label-free alternative for assessing tumor cell responses. While further dataset expansion and model refinement are necessary to enhance generalizability, these results underscore the potential of nanomotion technology as a rapid, phenotypic DST for personalized oncology. By directly measuring the mechanical behavior of cancer cells in response to chemotherapy, this method could transform clinical decision-making, enabling faster, more precise treatment strategies to combat drug resistance in cancer.


  • Open Access

    Nanomotion technology for testing azithromycin susceptibility of Salmonella enterica

    by Mariliis Hinnu, Toomas Mets, Ivana Kerkez, Marta Putrinš, Niilo Kaldalu, Gino Cathomen, Marta Pla Verge, Danuta Cichocka, Alexander Sturm, Tanel Tenson, et al.

    Invasive salmonellosis caused by Salmonella enterica subspecies affects millions of people every year, mostly children from low-income countries, and is associated with a high mortality rate. Azithromycin is used to treat invasive salmonellosis resistant to first-line drugs despite conflicting effective concentrations in vitro and achievable serum concentrations in vivo . As resistance levels to azithromycin are rising, we demonstrate that nanomotion technology, which is based on measuring changes in bacterial nanoscale movements, can be used for rapid phenotypic testing of Salmonella ’s susceptibility to azithromycin. Additionally, the use of nanomotion enabled the detection of the bactericidal effect. Nanomotion changes under various culture conditions correlated with susceptibility measured by minimum inhibitory concenctration (MIC) determination, colony-forming unit (CFU) counting, and fluorescent reporter-based estimates of intrabacterial azithromycin accumulation. Environmental conditions, both during azithromycin treatment and throughout the recovery period, significantly affect the antibacterial response to azithromycin. Azithromycin susceptibility in Salmonella is detectable after only 2 h of treatment. This reflects the quick action of the antibiotic, which could be one of the contributing factors behind the clinical efficacy of azithromycin for Salmonella treatment. Our study underscores the critical role of assay conditions, which greatly influenced both azithromycin efficacy and the test results. IMPORTANCE: Azithromycin is used as a last-resort antibiotic to treat life-threatening infections caused by Salmonella enterica , a high-priority pathogen according to the World Health Organization. Resistance levels to azithromycin are increasing, highlighting the need for rapid susceptibility testing. In this study, we demonstrate that nanomotion technology can detect azithromycin susceptibility in Salmonella , suggesting its potential use for rapid resistance detection in clinical settings and its future use with azithromycin. Additionally, the study shows that nanomotion technology can be used for susceptibility and postantibiotic effect testing for various pathogens and antibacterials, including those generally regarded as bacteriostatic.


  • Open Access

    Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis

    by Anthony Vocat, Amanda Luraschi-Eggemann, Claudia Antoni, Gino Cathomen, Danuta Cichocka, Gilbert Greub, Olga Riabova, Vadim Makarov, Onya Opota, Alfonso Mendoza, et al.

    Novel drugs and improved diagnostics for Mycobacterium tuberculosis (MTB) are urgently needed and go hand in hand. We evaluated the in vitro activity of two benzothiazinone drug candidates (MCZ, PBTZ169; BTZ043) and their main metabolites against MTB using advanced nanomotion technology. The results demonstrated significant reductions in MTB viability within 7 h, indicating the potential for rapid, precise antibiotic susceptibility testing based on a phenotypic read-out in real time. PBTZ169 and H 2 -PBTZ169 achieved 100% separation between the susceptible H37Rv and a resistant dprE1 mutant strain NTB1. These findings support nanomotion technology’s potential for faster antibiotic susceptibility testing of novel MTB drug candidates targeting the DprE1 enzyme that could reduce empirical treatment duration and antibiotic resistance selection pressure due to inaccurate treatments.


  • Open Access

    Nanomotion technology: an innovative method to study cell metabolism in Escherichia coli, as a potential indicator for tolerance

    by Christèle Aubry, Carole Kebbi-Beghdadi, Amanda Luraschi-Eggemann, Gino Cathomen, Danuta Cichocka, Alexander Sturm, Gilbert Greub

    Introduction. Antibiotic tolerance corresponds to the bacterial ability to survive a transient exposure to antibiotics and is often associated with treatment failure. Current methods of identifying tolerance based on bacterial growth are time-consuming. This study explores the use of a growth-independent method utilizing nanomotion technology to detect antibiotic-tolerant bacteria. Hypothesis. The nanomotion signal obtained from a nanomechanical sensor measures real-time metabolic activity and cellular processes and could provide valuable information about the tolerance of bacteria to antibiotics that cannot be detected by standard antibiotic susceptibility tests. Aim. The aim of this study is to investigate the potential of nanomotion technology to record antibiotic-tolerant bacteria. Methodology. We generated a slow-growing Escherichia coli strain by manipulating mazF expression levels and confirmed its viability by several standard methods. We subsequently measured its nanomotion and the nanomotion of the WT E. coli in the presence or absence of antibiotics. Supervised machine learning was employed to distinguish slow-growing from exponentially growing bacteria. Observations for bacterial nanomotions were confirmed by standard kill curves. Results. We distinguished slow-growing from exponentially growing bacteria using specific features from the nanomotion signal. Furthermore, the exposition of both growth phenotypes to polymyxin decreased the nanomotion signal indicating cell death. Similarly, when exponentially growing cells were exposed to ampicillin, an antibiotic whose efficacy depends on the growth rate, the nanomotion signal also decreased. In contrast, the nanomotion signal remained unchanged for slow-growing bacteria upon exposure to ampicillin. In addition, antibiotic exposure can cause bacterial elongation, in which the biomass of a cell increases without cell division. By overexpressing sulA, we mimicked antibiotic-induced elongation. Differences in the nanomotion signal were observed when comparing elongating and non-elongating phenotypes. Conclusion. This work shows that nanomotion signals entail information about the reaction to antibiotics that standard MIC-based antibiotic susceptibility tests cannot detect. In the future, nanomotion-based antibiotic tolerance tests could be developed for clinical use in chronic or relapsing infections.


  • Open Access

    Nanomotion technology for testing azithromycin susceptibility of Salmonella enterica

    by Mariliis Hinnu, Toomas Mets, Ivana Kerkez, Marta Putrinš, Niilo Kaldalu, Gino Cathomen, Marta Pla Verge, Danuta Cichocka, Alexander Sturm, Tanel Tenson

    Azithromycin is used to treat invasive salmonellosis, despite conflicting effective concentrations in vitro and in vivo . Resistance of Salmonella enterica to azithromycin is increasing. We demonstrate that nanomotion technology can be used for rapid phenotypic testing of Salmonella ’s susceptibility to azithromycin. Nanomotion changes under various culture conditions correlated with susceptibility measured by MIC determination, CFU counting, and fluorescent reporter-based estimates of intrabacterial azithromycin accumulation.


  • Open Access

    Accurate and rapid antibiotic susceptibility testing using a machine learning-assisted nanomotion technology platform

    by Alexander Sturm, Grzegorz Jóźwiak, Marta Pla Verge, Laura Munch, Gino Cathomen, Anthony Vocat, Amanda Luraschi-Eggemann, Clara Orlando, Katja Fromm, Eric Delarze, et al.

    Antimicrobial resistance (AMR) is a major public health threat, reducing treatment options for infected patients. AMR is promoted by a lack of access to rapid antibiotic susceptibility tests (ASTs). Accelerated ASTs can identify effective antibiotics for treatment in a timely and informed manner. We describe a rapid growth-independent phenotypic AST that uses a nanomotion technology platform to measure bacterial vibrations. Machine learning techniques are applied to analyze a large dataset encompassing 2762 individual nanomotion recordings from 1180 spiked positive blood culture samples covering 364Escherichia coliandKlebsiella pneumoniaeisolates exposed to cephalosporins and fluoroquinolones. The training performances of the different classification models achieve between 90.5 and 100% accuracy. Independent testing of the AST on 223 strains, including in clinical setting, correctly predict susceptibility and resistance with accuracies between 89.5% and 98.9%. The study shows the potential of this nanomotion platform for future bacterial phenotype delineation.


  • Open Access

    Genetic factors affecting storage and utilization of lipids during dormancy in Mycobacterium tuberculosis

    by Alexander Sturm, Penny Sun, Julian Avila-Pacheco, Anne E. Clatworthy, Zohar Bloom-Ackermann, Michael G. Wuo, James E. Gomez, Soomin Jin, Clary B. Clish, Laura L. Kiessling, et al.

    Tuberculosis is a global threat, with ~10 million yearly active cases. Many more people, however, live with “latent” infection, where Mycobacterium tuberculosis survives in a non-replicative form. When latent bacteria activate and regrow, they elicit immune responses and result in significant host damage. Replicating and non-growing bacilli can co-exist; however, non-growing bacteria are considerably less sensitive to antibiotics, thus complicating treatment by necessitating long treatment durations. Here, we sought to identify genes important for bacterial survival in this non-growing state using a carbon starvation model. We found that a previously uncharacterized gene, omamC , is involved in storing and utilizing fatty acids as bacteria transition between these two states. Importantly, inhibiting lipid metabolism using a lipase inhibitor eradicates non-growing bacteria. Thus, targeting lipid metabolism may be a viable strategy for treating the non-growing population in strategies to shorten treatment durations of tuberculosis.


  • Open Access

    Antibiotic action revealed by real-time imaging of the mycobacterial membrane

    by Michael G. Wuo, Charles L. Dulberger, Robert A. Brown, Alexander Sturm, Eveline Ultee, Zohar Bloom-Ackermann, Catherine Choi, Ethan C. Garner, Ariane Briegel, Deborah T. Hung, et al.

    The current understanding of mycobacterial cell envelope remodeling in response to antibiotics is limited. Chemical tools that report on phenotypic changes with minimal cell wall perturbation are critical to understanding such time-dependent processes. We employed a fluorogenic chemical probe to image how antibiotics perturb mycobacterial cell envelope assembly in real-time. Time-lapse microscopy revealed that differential antibiotic treatment elicited unique cellular phenotypes, providing a platform for simultaneously monitoring cell envelope construction and remodeling responses. Our data show that rifampicin, which does not directly inhibit cell wall biosynthesis, affords a readily detected mycomembrane phenotype. The fluorogenic probe revealed the production of extracellular vesicles in response to antibiotics, and analyses of these vesicles indicate that antibiotic treatment elicits the release of agents that attenuate macrophage activation.